 Download PDF
|
| Market: Hong Kong | Ticker: 690 | ISIN: KYG9198H1406 | Industry: Healthcare |
Uni-Bio Science Group is a leading Chinese biopharmaceutical healthcare company focusing on the four strategic areas of bio-innovative drugs, high-value generic drugs, medical cosmetology, and CMO, integrating R&D, production and sales. The Company is focused on addressing high unmet medical needs via the development and commercialisation of highly innovative therapies.
Led by a highly experienced management team and Board of Directors with broad international pharmaceutical and commercial experience, Uni-Bio Science Group Ltd was founded in 2001 and is listed on the Hong Kong Stock Exchange (Stock Code: 0690).
Uni-Bio Science Group Ltd has developed unparalleled expertise in the research, development and manufacturing of pharmaceuticals to world-class standards. The Group leverages its broad commercial presence in China for its proprietary portfolio of marketed pharmaceutical products and the products of its partners.
Key Products
Uni-Bio is built upon the vision of addressing the pressing needs in the provision of high-quality Chinese healthcare solutions.
Uni-Bio has a growing pipeline of novel treatments and marketed products which demonstrate strong therapeutic advantages for patients in the disease areas most in need of new solutions to growing healthcare problems – endocrinology, ophthalmology, dermatology and medical cosmetology.
Led by a highly experienced management team and Board of Directors with broad international pharmaceutical and commercial experience, Uni-Bio Science Group Ltd was founded in 2001 and is listed on the Hong Kong Stock Exchange (Stock Code: 0690).
Uni-Bio Science Group Ltd has developed unparalleled expertise in the research, development and manufacturing of pharmaceuticals to world-class standards. The Group leverages its broad commercial presence in China for its proprietary portfolio of marketed pharmaceutical products and the products of its partners.
Key Products
Uni-Bio is built upon the vision of addressing the pressing needs in the provision of high-quality Chinese healthcare solutions.
Uni-Bio has a growing pipeline of novel treatments and marketed products which demonstrate strong therapeutic advantages for patients in the disease areas most in need of new solutions to growing healthcare problems – endocrinology, ophthalmology, dermatology and medical cosmetology.
| Marketed products | Lead clinical development programs |
|
|
Expansion Strategy
China’s well-documented ageing population and growing population places great strain on our healthcare systems, however Uni-Bio has built broad capability to address this challenge both in the breadth of its product portfolio and experienced commercial function.
Uni-Bio is focused on delivering against its strategic priorities to achieve sustainable growth for the Group:
China’s well-documented ageing population and growing population places great strain on our healthcare systems, however Uni-Bio has built broad capability to address this challenge both in the breadth of its product portfolio and experienced commercial function.
Uni-Bio is focused on delivering against its strategic priorities to achieve sustainable growth for the Group:
-
To grow its diversified portfolio of innovative treatments and healthcare solutions through partnerships that address high unmet medical need to patients in China;
-
To realise the broad growth opportunities presented by the changing dynamic of the Chinese healthcare market which favour Uni-Bio’s focus on innovation;
- Through enhancing product quality and effectively reduce cost, it brings much more better drug with economical price, so to boost the sales;
-
To increase the breadth of its sales coverage beyond the key provinces where the Company already has a strong geographic footprint.
Uni-Bio’s ultimate goal is to build a leading, sustainable organization that builds and delivers shareholder value by efficiently executing a number of growth strategies.
| Share Data | 30/04/2025 | ||
|---|---|---|---|
| Currency | HKD | Volume | 480,000 |
| Previous Close | 0.075 | Number of Shares | 5,971,228,147 |
| Change (%) | 1.35 | Market Cap (mil) | 447.84 |
Notes:
(1) Ratio equals to total liabilities/total equity. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Uni-Bio Science Group Ltd Unit 502, 5/F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, Hong Kong Telephone: (852) 31023232 E-mail: ir@uni-bioscience.com |
Supplied by ©
|
| Share Data | 30/04/2025 |
|---|---|
| Currency | HKD |
| Previous Close | 0.075 |
| Change (%) | 1.35 |
| Volume | 480,000 |
| Number of Shares | 5,971,228,147 |
| Market Cap (mil) | 447.84 |
| Key Figures (HK$’000) | 12M 2022 | 12M 2023 | 12M 2024 |
|---|---|---|---|
| For the year ended 31 December | |||
| Revenue | 440,316 | 484,718 | 552,980 |
| Gross profit | 334,883 | 392,818 | 461,068 |
| Adjusted EBITDA | 66,108 | 99,445 | 122,458 |
| Profit for the year | 38,512 | 70,876 | 82,774 |
| As at 31 December | |||
| Total assets | 292,471 | 409,992 | 517,552 |
| Total liabilities | 97,725 | 152,818 | 191,907 |
| Total equity | 194,746 | 257,174 | 325,645 |
| Total fixed assets | 41,850 | 87,247 | 117,818 |
| Earnings per share (HK cents) | |||
| Basic | 0.61 | 1.11 | 1.35 |
| Diluted | 0.61 | 1.11 | 1.35 |
| Financial Indicators | |||
| Gross profit margin (%) | 76.1 | 81.0 | 83.4 |
| Current ratio (times) | 2.22 | 2.07 | 2.58 |
| Total liabilities to total asset ratio (%) | 33.4 | 37.3 | 37.1 |
| Debt to equity ratio(1) (%) | 50.2 | 59.4 | 58.9 |
Notes:
(1) Ratio equals to total liabilities/total equity.
(1) Ratio equals to total liabilities/total equity.
Supplied by ©